Podcasts about microbicides

Today's conversation with my good friend Yasmin Halima is truly a unique one. Yasmin is an award-winning global health executive who has mobilized partnerships that have shifted government policy, shaped clinical research and expanded treatment and prevention options for patients. She has worked with the Gates Foundation, the Global Campaign for Microbicides, global PR agency Burson-Marsteller, and Right to Care in South Africa, and she has chaired congressional briefings and served on the boards of AIDS advocacy coalitions. With over two decades in global health, Yasmin has impacted health regulations and standards in countries across the world. From her childhood in Gujarat, India, to growing up in the heart of industrial England, and later moving the U.S. to expand her education and make a bigger impact, Yasmin's fierce independence has focused on creating opportunities for women of color. She co-founded the Yasmin Leadership Academy with her daughter, Dr. Seema Yasmin, a physician, professor, and journalist. The Yasmin Leadership Academy nurtures future women leaders and challenges gendered attributes of power and leadership.Yasmin's story truly tells the power of one person choosing to live with courage and use her voice—which opens doors not only for herself and her own daughter, but for people around the world.Learn more here:The Yasmin Leadership AcademySeema YasminQ&A with mother and daughterHow can you use the voice you have to live with more soul? Let me know on IG @coach_chrisrodriguez. For all episodes and info about my coaching program, visit me at www.coachchrisrodriguez.com.Be sure to subscribe and leave a review on your favorite podcast platform!

Ben is joined by Micheal Ighodaro, a Nigerian-born human rights activist, who is profiled in the new HBO documentary, "The Legend of the Underground," a film about the struggle against rampant LGBTQ discrimination in Nigeria, as experienced by several young men who fight for the right to live their truth.You can find this episode and past episodes of A Shot in the Arm Podcast with Ben Plumley on this (and other) podcast platforms. Please subscribe and give us 5 stars!https://www.hbo.com/documentaries/the-legend-of-the-undergroundhttps://www.avac.orghttps://www.gbgmc.org/global-black-pridehttps://outrightinternational.orghttps://frontlineaids.orghttps://www.hunuvat.comhttps://newsdocmedia.comhttps://www.unaids.orghttps://www.who.int#HIV #AIDS #LGBTQ #humanrights #TheLegendOfTheUnderground #HBODocs #GlobalBlackPride #AccessToTreatment #Nigeria #asylumrights #COVID19 #microbicides

Lisa Carlton, PhD, understands rare childhood diseases both professionally and personally. She was already a scientist specializing in rare diseases when her daughter was diagnosed with one: tuberous sclerosis. As VP of Global Regulatory Affairs for a biotech drug developer she is involved in development of treatments for other rare diseases too. This makes her an ideal person to co-chair an industry-patient-advocacy group called the Working Group on Regulatory Science, a part of the EveryLife Foundation for Rare Disorders that seeks to advance the development of treatment and diagnostic opportunities for rare disease patients through science-driven public policy.Tuberous sclerosis, a rare genetic disorder, affects one in every 6,000 newborns in the United States. It is a disorder that causes benign growth in almost any tissue; it’s of particular concern when it occurs in the brain, lungs or kidneys. Some people who have tuberous sclerosis may have learning problems or difficult-to-control seizures. Her daughter—one of a pair of twins—was diagnosed in utero. She’s doing well, although the speech and language disorders associated with the condition have made it hard to access the curriculum in school. Dr. Carlton talks about the challenges of developing new treatments for rare diseases and the approaches taken to try to overcome them. She also talks about her daughter’s disease, and how families can bring their best to their journey as they adapt to support their child. Based on her experience as a parent and advocate—as well as her experience in the industry—she has this advice for families: “Take a breath.” Drug development is slow, especially in rare diseases. “You are in for a marathon of supporting your child.” When possible, connect with other parents and advocacy groups. Or build your own tribe—work, friends, family, etc. “You have to be healthy and rested enough to do this. You have to be at your best.” She’s often asked how she manages to keep going. “I don’t know how I wouldn’t do it. You’ve been given this gift of a special child. Now it’s time to find your tribe and push ahead.”Her advice for a biotech company considering launch of a clinical trial for a rare disease? Nobody knows more about a patient’s journey, the patient’s experience, than the patient—or a parent or caregiver. “Just listen to what patients are saying. You are going to learn a lot.”Lisa Carlton, PhD, has previously worked in regulatory roles at the National Institutes of Health, Otsuka Pharmaceuticals and International Partnership for Microbicides. She is currently serving as Vice President of Global Regulatory Affairs at REGENXBIO, a gene therapy-focused biotech company with headquarters in Rockville, MD. Lisa received her PhD in Pharmaceutics and MS in Medicinal Chemistry from the University of North Carolina in Chapel Hill and a BS in Biochemistry from North Carolina State University.

Highly driven and articulate biomedical scientist and educator with expert knowledge in HIV/AIDS virology, clinical disease/pathogenicity, drug treatments and drug resistance development. Exceptionally gifted in communicating abstract concepts to audiences of diverse education backgrounds whilst effectively advocating an idea, product and/or organization. Strongly pursued for advisory, communication and training skills throughout career with success targeting large groups impacting direction and perception of new HIV infection prevention strategies and technologies. Skilled writer as demonstrated by impressive publication record with an intrinsic passion to empower others with knowledge.

In March, initial results from the two open-label trials of the dapivirine vaginal ring (HOPE and DREAM) showed that adherence and efficacy improved over the earlier Phase III trials. Learn more about all these trials at https://www.avac.org/podcast/dapivirine-ring. Meanwhile, The ring is also advancing along the pathway to licensure. If approved, it will be the next major prevention option available since the US FDA approved oral PrEP in 2012. In this episode, Zeda Rosenberg of the International Partnerships for Microbicides, which developed the ring, explains the latest findings and spells out how, when, where and if the ring might become an available tool. A trial participant and community leader in Uganda, Ruth* pulls back the curtain on the ups and downs of using the ring, and a Ugandan investigator with the REACH study, Carolyne Akello of the Makere University- Johns Hopkins University Research Collaboration, explains the importance of this trial, the next step in testing the potential of this monthly vaginal ring for young women.

Tim's ancestors hail from Ireland. They entered the United States through Canada, several generations ago, to find warmer climes, eventually settling in the Dakotas. Tim is a long-time resident of New York City and has traveled extensively in Africa, South Asia and Europe. He pursues a lifelong goal of fluency in French and Italian, and studies classical singing. Tim’s professional global health training ground was the Population Council, a premier international non-profit, non-governmental institution that conducts biomedical, public health, and social science research, helping to build research capacities in developing countries. He joined the Council in 1991, and was promoted to play a leading role in external relations, public affairs, and fundraising. During his tenure, the Council’s unrestricted funding from foreign governments increased by 132%, and new funding schemes were established with the Governments of Japan, New Zealand, and the U.K. He also served as the primary point of contact with the international NGO community and with the U.S. Government, managing the Council’s $13 million co-operative agreement with the U.S. Agency for International Development.  From 1998-2001, Tim was a senior consultant at the London-based communications agency InterScience, working with a range of clients on their sexual and reproductive health programs. When InterScience folded in 2001, he continued consulting privately. By analyzing policy trends, programmatic developments, donor priorities, and a vast range of research, he helped clients shape their communications programs, fundraising strategies, and address their organizational development needs.  Some of his major clients were the Rockefeller Foundation, the International Council of AIDS Service Organizations; the International AIDS Vaccine Initiative; the International Partnership for Microbicides; the Guttmacher Institute; GlaxoSmithKline’s Positive Action program and GSK Biologicals.  In April 2006, Tim was appointed Executive Director of the Staying Alive Foundation at MTV Networks International based in New York.  A global grant-making and advocacy organization, the Foundation encourages and enables young people who are involved in HIV and AIDS awareness, education and prevention campaigns.  When MTV changed its philanthropic directions, Tim returned to private consulting.  In late 2008, The Bill and Melinda Gates Foundation awarded a $12m, 3-year grant to launch The Maternal Health Task Force, and the CEO of its host NGO (EngenderHealth) called in Tim to spearhead the process of turning the proposal into a project.  Starting with public announcements and events throughout the global public health world using an array of interpersonal and electronic communications vehicles, soon the MHTF was ensconced as a vital convening, coordinating and catalyzing entity in the maternal health field.  When the MHTF moved to the Harvard School of Public Health In 2011 with an increased Gates grant and several other major donors including the MacArthur Foundation, Tim continued as Senior Advisor on a broad range of communication and policy projects.  From 2014-2016, Tim was a Senior Program Officer at the Gates Foundation.  His portfolio spanned the continuum of sexual, reproductive, maternal, newborn, child and adolescent health policy and communication with grants at the global and country levels.  Starting in 2017, Tim re-launched his consultancy, "timothythomasdotnet" where he continues his work to improve the health and well-being of women and girls everywhere.  He graduated with honors from the Interlochen Arts Academy; he holds a Bachelors of Arts degree from Iowa State University and a Masters of Fine Arts degree from New York University. 

Microbicides that kill HIV in the lab often fail in clinical trials. A study finds that semen may be the culprit. Cynthia Graber reports  

Microbicides that kill HIV in the lab often fail in clinical trials. A study finds that semen may be the culprit. Cynthia Graber reports  

http://www.einstein.yu.edu - With the help of animations, Betsy Herold, M.D. shows why some drugs that prevented HIV and herpes transmission in the lab failed to protect women in clinical trials. See how proteins in semen act as an “invisibility cloak” for HIV and herpes viruses allowing them to bypass drugs and infect cells. Using lab techniques informed by clinical results, Dr. Herold conducts translational research on the next generation of drugs to prevent HIV and HSV infection. She is professor of pediatrics and of microbiology and immunology at Albert Einstein College of Medicine and chief, division of pediatric infectious diseases at The Children’s Hospital at Montefiore.

Vincent, Alan, Rich, and Judy Lieberman review the use of CD4 aptamer-siRNA chimeras to inhibit HIV transmission.

John McConnell discusses reviews on microbicides for HIV prevention, and Hepatitis E, and highlights the Nobel Prize for Medicine featured in this month's Leading Edge.